Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes
NCT ID: NCT06989697
Last Updated: 2025-05-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
80 participants
INTERVENTIONAL
2025-01-01
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment Associated With CSVD
NCT06495476
Efficacy and Safety of Ginkgo Biloba in Middle-aged Cognitively Intact Adults
NCT02181972
Efficacy and Safety of Ginkgo Biloba Extract in Mild Cognitive Impairment and Cerebrovascular Insufficiency
NCT00446485
Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease
NCT03090516
Efficacy and Safety of Qinggongshoutao Bolus in aMnestic Mild Cognitive Impairment
NCT02982603
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cilostazol & Ginko Leaf Dried Ext.
Renexin CR tab (cilostazol 200mg / Ginko Leaf Dried Ext. 160mg)
Cilostazol / Ginko Leaf Dried Ext.
Patients will receive a light green, oval-shaped, sustained-release film-coated tablet containing a combination of cilostazol (200 mg) and ginkgo biloba extract (160 mg), administered orally once daily.
Placebo
Placebo
Placebo
Patients will receive a placebo identical in taste, aroma, and formulation to the active treatment, administered orally once daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cilostazol / Ginko Leaf Dried Ext.
Patients will receive a light green, oval-shaped, sustained-release film-coated tablet containing a combination of cilostazol (200 mg) and ginkgo biloba extract (160 mg), administered orally once daily.
Placebo
Patients will receive a placebo identical in taste, aroma, and formulation to the active treatment, administered orally once daily.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adults aged 60 years or older
* Patients with a Mini-Mental State Examination (MMSE) score between 24 and 28 within the past 3 months
Exclusion Criteria
* Patients with poorly controlled blood glucose (HbA1c \> 10.0%)
* Patients with an MMSE score below 24
* Patients diagnosed with dementia (e.g., Alzheimer's disease)
* Patients with suspected cognitive impairment due to other causes
* Patients requiring antiplatelet or anticoagulant therapy other than the investigational product
* Patients with thyroid dysfunction requiring treatment (i.e., abnormal TSH levels)
* Patients with severe depression
* Patients with severe infections, recent surgery (perioperative status), or major trauma
* Patients with pituitary or adrenal insufficiency
* Patients with other medical conditions requiring hospitalization
* Patients with a history of alcohol or drug abuse within 1 year prior to screening
* Patients with a history of taking medications that may affect cognitive function within 3 months prior to screening
* Patients deemed by the investigator to be otherwise unsuitable for study participation
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SK Chemicals Co., Ltd.
INDUSTRY
Seoul National University Bundang Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Soo Lim
Clinical Professor and Principal Investigator, Division of Endocrinology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Bundang Hospital
Seongnam-si, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B-2402-880-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.